ENXTPA:NANOBiotechs
Nanobiotix (ENXTPA:NANO): Valuation Update Following Promising Clinical Data and Strong Financial Results
Nanobiotix (ENXTPA:NANO) is drawing a lot of market attention following the recent presentation of encouraging Phase 1 clinical data for JNJ-1900 (NBTXR3) in both esophageal and head and neck cancers. The timing comes at the same time as improvements in the company’s interim financial results, raising questions about future growth potential.
See our latest analysis for Nanobiotix.
Nanobiotix’s latest clinical breakthroughs and a turnaround in financial performance have supercharged momentum,...